Application of Arteridin protein in preparation of medicine for inhibiting angiogenesis
By using Arteridin protein to inhibit the STAT3 signaling pathway, the problem of poor reactivity of existing angiogenesis inhibitor drugs is solved, effective regulation of vascular endothelial cells is achieved, pathological angiogenesis is significantly inhibited, and an endogenous and effective Treatment strategies.
Patent Information
- Application Number
- CN202411179678.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-12-03
AI Technical Summary
Existing angiogenesis inhibitors have poor response to 50% of cases, and exogenous angiogenesis inhibitors have problems with immune rejection and insufficient tissue affinity, making it difficult to effectively inhibit pathological angiogenesis.
Arteridin protein is used as an endogenous angiogenic inhibitor. By inhibiting STAT3 phosphorylation and entry into the nucleus, it regulates the proliferation, migration and duct formation of vascular endothelial cells, and has been developed to inhibit angiogenic drugs, including the nucleic acid sequence of the Arteridin protein-encoded gene and Related detection reagents and drug carriers.
Arteridin protein significantly inhibits pathological angiogenesis in human endothelial cells and mouse tumor models, has high tissue affinity and low immune rejection, and has become a potential therapeutic target and strategy for angiogenesis-related diseases.
Smart Images

Figure CN119055746A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to an application of Arteridin protein in the preparation of a drug for inhibiting angiogenesis. Background Art
[0002] Angiogenesis is the biological process by which new blood vessels sprout from pre-existing vessels through budding and intussusception. It plays a crucial role in physiological conditions such as tissue regeneration, as well as pathological conditions such as diabetic retinopathy and tumor growth. Endothelial cells, lining the vascular wall, play a crucial role in angiogenesis. Under healthy conditions, endothelial cells are mostly quiescent. However, upon exposure to pathological stimuli, such as external injury, the expression of angiogenic growth factors, such as vascular endothelial growth factor (VEGF), angiogenin, and platelet-derived endothelial growth factor (PDGF), increases, inducing endothelial cell activation and significantly increasing their proliferation, migration, and angiogenesis, leading to pathological angiogenesis. Currently, drugs developed to target these angiogenic factors, such as pegaptanib and ranibizumab, are only effective in 50% of cases, suggesting that the mechanisms of angiogenesis require further elucidation. Endogenous angiogenesis inhibitors, such as PEDF, exist within the body and inhibit angiogenesis. Compared with exogenous angiogenesis inhibitors, endogenous angiogenesis inhibitory proteins have advantages such as high tissue affinity and low immune rejection, and are expected to become a new strategy for pathological angiogenesis. Summary of the Invention
[0003] The present invention aims to solve at least one of the technical problems in the related art to a certain extent. To this end, the main purpose of the present invention is to provide a use of Arteridin protein in the preparation of a drug for inhibiting angiogenesis.
[0004] The purpose of the present invention is achieved through the following technical solutions:
[0005] Application of Arteridin protein in the preparation of drugs for inhibiting angiogenesis.
[0006] Preferably, the nucleic acid sequence encoding the Arteridin protein is shown as SEQ ID No. 1.
[0007] Furthermore, the angiogenesis includes endothelial cell angiogenesis, retinal angiogenesis and tumor angiogenesis.
[0008] Preferably, the Arteridin protein is capable of inhibiting STAT3 phosphorylation and nuclear translocation.
[0009] Application of reagents for detecting Arteridin protein expression in the preparation of products for the diagnosis and treatment of angiogenesis.
[0010] Preferably, the product comprises an Arteridin protein detection reagent.
[0011] Furthermore, the detection reagent includes a reagent used to detect the expression level of the Arteridin protein encoding gene by a fluorescent quantitative PCR method.
[0012] Preferably, the drug / agent further comprises a pharmaceutically acceptable carrier, such carriers including (but not limited to): diluents, buffers, suspensions, emulsions, granules, encapsulations, excipients, fillers, adhesives, sprays, transdermal absorbents, wetting agents, disintegrants, absorption enhancers, surfactants, colorants, flavoring agents or adsorption carriers.
[0013] The drugs / agents of the present invention can be prepared into various dosage forms as needed, including but not limited to tablets, solutions, granules, patches, ointments, capsules, aerosols or suppositories.
[0014] The administration route of the drug / agent of the present invention is not limited, as long as it can exert the desired therapeutic or preventive effect, including but not limited to oral, intravenous injection, intramuscular injection, subcutaneous injection, sublingual, rectal irrigation, nasal spray, oral spray, local skin or systemic transdermal administration.
[0015] The drug / agent of the present invention can also be used in combination with other drugs for treating angiogenesis. The combined use of multiple drugs can greatly increase the success rate of treatment.
[0016] About the definition content:
[0017] The term "detection" is used herein in the broadest sense to include both qualitative and quantitative measurement of a target molecule. Detection includes merely identifying the presence of a target molecule in a sample as well as determining whether the target molecule is present in the sample at a detectable level.
[0018] The sequence of the Arteridin protein of the present invention can be found in public databases. It is transcribed from the LOC680254 gene, and the specific sequence is shown in SEQ ID NO. 1.
[0019] AtgggccaacgtttctttcttattggacaaagAGATCGAAGAAGCTGCTTTATCTTACAGTCACCCAAGGGGGAGCGCCTTCTTCCTTCCCAGAGTGGAGTGGCAGTGGGTCCGGGATTCTGGGATATGCACAGGGTCTGCGCCCTGCGCCCTGTCCGCGCTGAAGCTGAACTTGTCATTGGTTTGCAACAGCATGGTGAAGAAGTGTGGTGTGGATGGACG GACGGGCCTCTCAGGCACATGAAATACTCAAAGCCCAGTATTAACCAAACATGTTTCTCTGTTTTGTCTTTGATCTTTGTGCAGTGTTGGCTTTTTCCTTAATGATGTCACTTGTATTTTATTTTTGGTTTATTTGTAGACTGTCTCCCTCCTTGGCCATGGCTTTACTTTTATGTCCACCCAAGGAGAGTTTCACCAGTTTAGGTTTAAGAAATTAC;
[0020] Compared with the prior art, the present invention has at least the following advantages:
[0021] The present invention discovered for the first time the expression of Arteridin protein in vascular endothelial cells, and its expression is related to angiogenesis. As a new endogenous angiogenesis inhibitory protein, Arteridin can effectively maintain endothelial cell function and regulate angiogenesis, significantly inhibiting pathological functions in human endothelial cells and mouse tumor models, and is expected to become a target and strategy for the treatment of angiogenesis-related diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] In order to more clearly illustrate the specific embodiments of the present invention, the following briefly introduces the drawings required for the specific embodiments or the description of the prior art.
[0023] Figure 1 This is a construction map of the human Arteridin protein overexpression adenovirus in Example 1 of the present invention;
[0024] Figure 2 The immunoblotting experiment in Example 1 of the present invention verifies the overexpression efficiency of human Arteridin overexpression adenovirus;
[0025] Figure 3 The proliferation, migration, and tube formation of vascular endothelial cells after overexpression of human Arteridin protein in Example 1 of the present invention;
[0026] Figure 4 The human Arteridin protein inhibits STAT3 phosphorylation and nuclear translocation in Example 1 of the present invention;
[0027] Figure 5 This is a map of the rats with systemic overexpression of Arteridin protein in Example 2 of the present invention;
[0028] Figure 6 The retinal angiogenesis of Arteridin protein overexpression and knockout rats and wild-type rats in Example 2 of the present invention;
[0029] Figure 7 A map was prepared for the mouse endothelial cell-specific Arteridin protein overexpression adeno-associated virus in Example 3 of the present invention;
[0030] Figure 8 The growth and angiogenesis of subcutaneous tumor B16 in mice after endothelial-specific overexpression of Arteridin in Example 3 of the present invention are as follows:
[0031] Figure 9 This is the growth and angiogenesis of LLC subcutaneous tumors in mice after endothelial-specific overexpression of Arteridin in Example 3 of the present invention. DETAILED DESCRIPTION
[0032] In order to make the purpose, technical solutions and advantages of the present invention more clear, the present invention is further described in detail below with reference to the accompanying drawings and embodiments, but it should not be understood as limiting the scope of protection of the present invention. Any formal equivalent transformation based on the concept of the present invention should be considered as the scope of the present invention.
[0033] This document provides general and / or specific descriptions of the materials and experimental methods used in the experiments. Unless otherwise specified, all experimental or testing methods are conventional methods. All reagents and instruments used, unless the manufacturer is specified, are commercially available, conventional products and were prepared or used using conventional methods.
[0034] Arteridin protein has homology in humans, rats, and mice, mainly reflected in the following aspects: sequence homology: the ORF region encoding the Arteridin protein in rats and mice has a 92% sequence similarity (both are 117 amino acid residues long). The human Arteridin protein sequence (composed of 106 amino acid residues) has slightly lower sequence similarity (approximately 60% sequence identity with rats and mice) due to the presence of a frameshift mutation; the encoding genes are located at the same locus, both on the antisense strand of the RASAL2 gene, in the opposite direction of RASAL2 gene transcription; and functional conservation: they have the same functions of inhibiting proliferation, migration, and angiogenesis in vascular endothelial cells of different species.
[0035] Example 1: Arteridin protein inhibits vascular endothelial cell proliferation, migration and tube formation
[0036] This example studies the effect of Arteridin protein on vascular endothelial cells, specifically:
[0037] 1) Construction of human Arteridin protein overexpression adenovirus
[0038] We commissioned Hanbio Biotech (Shanghai) Co., Ltd. to construct a human Arteridin overexpression adenovirus. The specific construction process is as follows: Figure 1 The human RASAL2-AS1 ORF region sequence was synthesized and inserted into the pAdTrack-CMV-3flag vector by chemical base synthesis. Human Arteridin protein overexpression adenovirus was prepared through vector restriction enzyme digestion, target fragment amplification, vector and target fragment ligation, transformation, plasmid extraction, and adenovirus recombination. The sequence of the human RASAL2-AS1 ORF region is: atgggccaacgtttctttcttattggacaaagAGATCGAAGAAGCTGCTTTATCTTACAGTCACCCAAGGGGGAGCGCCTTCTTCCTTCCCAGAGTGGAGTGGCAGTGGGTCCGGGATTCTGGGATATGCACAGGGTCTGCGCCCTGCGCCCTGTCCGCGCTGAAGCTGAACTTGT CATTGGTTTGCAACAGCATGGTGAAGAAGTGTGGTGTGGATGGACGGACGGGCCTCTCAGGCACATGAAATACTCAAAGCCCAGTATTAACCAAACATGTTTCTCTGTTTTGTCTTTGATCTTTGTGCAGTGTGTT GGCTTTTTCCTTTAATGATGTCACTTGTATTTTATTTTTGGTTTATTTGTAGACTGTCTCCCTCCTTGGCCATGGCTTTACTTTTATGTCCACCCAAGGAGAGTTTCACCAGTTTAGGTTTAAGAAATTAC(SEQ ID NO.1);
[0039] Human Arteridin protein overexpression adenovirus was used to transfect human umbilical vein endothelial cells (HUVEC), and the control virus (empty vector overexpression adenovirus) was used as the control group. Total cell protein was extracted 48 hours after transfection, and the prepared human Arteridin protein overexpression adenovirus was identified by immunoblotting. The results are as follows: Figure 2As shown in the figure, it can be seen that Arteridin protein is successfully overexpressed in human umbilical vein endothelial cells.
[0040] 2) Effects of Arteridin protein on proliferation, migration, and tube formation of human umbilical vein endothelial cells;
[0041] To investigate the effects of Arteridin on the proliferation, migration, and tube formation of human umbilical vein endothelial cells, we performed a pH3 staining assay for cell proliferation, a scratch wound assay for cell migration, a transwell assay, and a Matrigel-based endothelial cell tube formation assay.
[0042] 21) The cell proliferation pH3 staining experiment includes the following steps:
[0043] (1) On the first day, HUVEC cells were plated (24-well plates, with one cell slide placed in each well), and 0.25 μl of human Arteridin protein overexpressing adenovirus and control virus (empty vector overexpressing adenovirus) were added to the corresponding wells.
[0044] (2) After 48 h, the culture medium was discarded, the cells were washed twice with PBS for 2 min each time, and fixed with 4% paraformaldehyde for 15 min;
[0045] (3) Wash with PBS three times, 2 min each time;
[0046] (4) 0.05% Triton X-100 permeabilization for 15 min;
[0047] (5) Immunofluorescence staining with blocking solution, 37°C, 30 min;
[0048] (6) Add primary antibody (PH3 1:200);
[0049] (7) Incubate overnight at 4°C;
[0050] (8) Remove the primary antibody and wash with PBS buffer three times, 2 min each time;
[0051] (9) Add secondary antibody (goat anti-rabbit 488 1:200) and incubate at 37°C in the dark for 1-2 h;
[0052] (10) DPAI dye was added for nucleus staining in the last 5 minutes;
[0053] (11) Protect from light and wash with PBS three times, 2 min each time;
[0054] (12) Add anti-fluorescence quenching agent, carefully seal the slide with a coverslip, store at 4°C, and photograph using a fluorescence microscope;
[0055] The results are as follows Figure 3As shown in (a), it can be seen from the figure that after overexpression of Arteridin in human umbilical vein endothelial cells, the proliferation ability is weakened.
[0056] 22) The cell migration scratch assay includes the following steps:
[0057] (1) On the first day, cells were plated (6-well plates) and 1 μl of human Arteridin protein overexpressing adenovirus and control virus were added to the corresponding wells.
[0058] (2) On the second day, when the cell confluence reaches more than 90%, streak vertically with a 100 μL sterile pipette tip;
[0059] (3) Discard the suspended cells and old culture medium, then wash with PBS buffer and replace with serum-free culture medium;
[0060] (4) Take photos under an inverted microscope, take photos at 0 h;
[0061] (5) Take photos again after 24 hours;
[0062] The results are as follows Figure 3 As shown in (b), it can be seen from the figure that after overexpression of Arteridin in human umbilical vein endothelial cells, the migration ability is weakened.
[0063] 23) The cell migration transwell cell chamber experiment includes the following steps:
[0064] (1) On the first day, cells were plated (24-well plate) and 0.25 μl of human Arteridin overexpressing adenovirus and control virus (empty vector overexpressing adenovirus) were added to the corresponding wells.
[0065] (2) The next day, the cells were digested with trypsin and resuspended in 1% FBS culture medium;
[0066] (3) Cell counting: Place the cell chamber in a 24-well plate and inoculate 1×10 cells per well. 4 cells in the upper chamber of the cell chamber, and the total volume was filled to 300 μL;
[0067] (4) Add 700 μL of complete culture medium to the lower chamber;
[0068] (5) After culturing in a cell culture incubator for 24 hours, the cells on the inner side of the upper chamber were gently wiped off with a cotton swab and then washed with PBS buffer;
[0069] (6) Fix with 4% paraformaldehyde for 15 min and wash with PBS buffer three times, 5 min each time;
[0070] (7) 1% crystal violet staining, room temperature, 2 h;
[0071] (8) Wash with PBS buffer three times, 5 min each time;
[0072] (9) Take photos under a microscope.
[0073] The results are as follows Figure 3 As shown in (c), the migration ability of human umbilical vein endothelial cells was weakened after overexpression of Arteridin.
[0074] 24) The Matrigel endothelial cell tube formation experiment includes the following steps:
[0075] (1) On the first day, cells were plated (24-well plate) and 0.25 μl of human Arteridin overexpressing adenovirus and control virus (empty vector overexpressing adenovirus) were added to the corresponding wells. Matrigel was thawed from -20°C to 4°C in advance. Sterile pipette tips were prepared in advance, wrapped with cloth, and placed at -20°C for later use.
[0076] (2) The next day, wrap the 48-well plate with cloth and place it in a 4°C refrigerator to precool.
[0077] (3) Place the pre-cooled 48-well plate / ibidi angiogenesis slide, pipette tips, and pre-thawed Matrigel on an ice box and operate on ice throughout the process.
[0078] (4) Place the 48-well plate / ibidi angiogenesis slide on ice and spread the gel: 150 μL of Matrigel per well of the 48-well plate and 10 μL of Matrigel per well of ibidi (placed in a wet box made of a 10 cm large dish and wet paper towels), place in a cell culture incubator, and allow to solidify after about 30 minutes;
[0079] (5) Digest the transfected cells with trypsin, centrifuge at 1000 rpm at 4°C for 5 min, resuspend, and count the cells;
[0080] (6) 1×10 per well 4 For each well, the amount of cell suspension added should be controlled at around 50 μL. Add the suspension vertically without touching the solidified gel underneath.
[0081] (7) Cover the lid and let it sit for a while. All cells will settle on the surface of the matrix gel.
[0082] (8) Place the cells in a cell culture incubator and observe the tubule formation at intervals of 2, 4, 6, and 8 hours;
[0083] (9) Take photos after 8 hours;
[0084] The results are as follows Figure 3 As shown in (d), the figure shows that after overexpression of Arteridin in human umbilical vein endothelial cells, the tube-forming ability is weakened.
[0085] 3) Through immunoblotting and nuclear-cytoplasmic fractionation experiments, it was demonstrated that Arteridin protein inhibits the phosphorylation and nuclear translocation of STAT3, thereby inhibiting the activity of the STAT3 signaling pathway. Specifically:
[0086] (1) Cultured human umbilical vein endothelial cells were divided into two groups. One group was injected with human Arteridin-overexpressing adenovirus, and the other group was injected with control virus (empty vector-overexpressing adenovirus).
[0087] (2) After 48 hours, total protein, nuclear protein, and plasma protein were extracted using a nuclear protein extraction kit;
[0088] (3) Perform immunoblotting experiments: prepare 1× electrophoresis buffer, add electrophoresis buffer to the electrophoresis tank and then load the sample, press the line at 70V, and turn to 100V to start running the gel after the bromophenol blue band press line is flat, and stop when the bands separate and the bromophenol blue runs to the bottom of the gel; Transfer membrane: prepare transfer solution, cut the gel according to the position of the target protein band, and then arrange the gel, NC membrane, and filter paper from top to bottom: sponge pad-filter paper-gel-NC membrane-filter paper-sponge pad. The protein transfers from the gel (negative electrode) to the membrane (positive electrode) at 100V, and the transfer time is set according to the protein molecular weight. After electroporation, the membrane is placed in the prepared 5% skim milk for blocking, shaken, and blocked at room temperature for 1-2 hours. The blocking solution on the membrane is rinsed with TBST, and then the primary antibody (STAT3 total protein, phosphorylated STAT3 (S727 and Y705), nuclear protein internal reference Histone H3, cytoplasmic protein internal reference GAPDH) is added, shaken, 4°C, overnight. The next day, the membrane is warmed to room temperature, and after 30 minutes, it is rinsed with TBST, once for 10 minutes, for a total of 3 times. According to the source of the primary antibody, the corresponding secondary antibody is selected for incubation (TBST preparation, 1:10000), incubated at room temperature, protected from light, for 1-2 hours. The membrane is rinsed with TBST 3 times, 10 minutes each time, and scanned using an Odyessy membrane scanner.
[0089] The results are as follows Figure 4 As shown in the figure, after overexpressing Arteridin protein in human umbilical vein endothelial cells (HUVEC), STAT3 and phosphorylated STAT3 were detected, indicating that Arteridin overexpression inhibited STAT3 phosphorylation. After overexpressing Arteridin protein, nuclear-cytoplasmic fractionation experiments were performed, followed by immunoblotting experiments to detect nuclear and cytoplasmic STAT3, indicating that Arteridin overexpression inhibited STAT3 nuclear import. As shown in the figure, after overexpression of Arteridin protein, the phosphorylation level of STAT3 was reduced, and nuclear import was also reduced.
[0090] Example 2: Study on the effect of Arteridin protein overexpression or knockout on retinal angiogenesis
[0091] This example provides a method for testing the effect of Arteridin protein on retinal angiogenesis, specifically:
[0092] 1) Construction of rats with systemic overexpression of Arteridin protein
[0093] The construction of Arteridin protein transgenic rats was commissioned by Beijing Weishanglide Biotechnology Co., Ltd. The rats were transgenic rats expressing the target protein Arteridin in the whole body based on the SD rat background. The specific construction process is as follows Figure 5 As shown;
[0094] The principle used is:
[0095] The PiggyBac transposon efficiently moves genetic elements between the vector and the genome through a "copy-and-paste" mechanism. During transposition, the transposase specifically recognizes the inverted terminal repeats (ITRs) at both ends of the transposon vector and effectively cleaves the ITRs and the sequence between them from their original positions on the transposon vector, efficiently integrating them into the TTAA site on the chromosome. Therefore, the target exogenous fragment is efficiently integrated into the rat genome, and then the constructed expression element is constructed between the two ITR elements of the PiggyBac transposon system. The constructed transgenic vector and transposase cRNA are then microinjected into fertilized eggs of SD rats to obtain transgenic rats that highly express the target protein.
[0096] The specific gene sequence of Arteridin protein (target exogenous fragment) is: RatLOC680254, CDS: 372bp (plus Kozad sequence and the required restriction enzyme sites for construction), specifically:
[0097] gctagcGCCACCATGGGAAAGGCGCTTCCCTTTCTTCTTAGCCCCTTCCCTGTTGATTTCTGGACCAATGCTTCTTTCTTGAACGAAGAGCATGAAGACGCTGCTTTATCTAACAGTCACCTTGGAGGAAACGCCATCGTTCTTCCAGAAGGGAGATCTGGCCCCCGGTCTTGGATTCTGAGATCAGT GCGAGATCCCGGCTCTGCGCCCTGTCCGCCCTGGAACTGGATTTATCATCAGTTTAGAATAGCATGGCTACGATGTGTGGTGTGGATGGATGGACGAGCCCCGCAAGTGCAAACAGGACAGTCCAGGTTACCTGACAAAGCAGCCACCGGTGCACCAGCTGTCCAAGATCAGACCTAGgtcgac(SEQ ID NO.2)
[0098] 2) Construction of Arteridin protein whole-body knockout rats
[0099] The construction of whole-body Arteridin protein rats was commissioned by Beijing Weishanglide Biotechnology Co., Ltd., and the whole-body target protein Arteridin knockout rats were constructed based on the SD rat background.
[0100] The construction principle is to use CRISPR-Cas9 to edit genomic DNA, inserting a single T base into the protein (Arteridin) coding region of the target gene LOC680254, forming a premature stop codon (TGA). Rat fertilized oocytes then undergo DNA repair through NHEJ, generating a frameshift mutation in the protein coding region, leading to premature termination of Arteridin protein translation and achieving the goal of knocking out the LOC680254 gene. The latest spCas91.1 is used to cut genomic DNA, reducing off-target effects.
[0101] The CDS sequence of the LOC680254 gene with the frameshift mutation caused by the insertion of the T base is as follows (the bold and underlined characters indicate the premature stop codon caused by the insertion of the T base);
[0102]
[0103] 3) Effects of Arteridin protein on retinal angiogenesis
[0104] The retinas of rats with systemic overexpression of the constructed Arteridin protein and rats with systemic knockout of Arteridin were stained using the following method:
[0105] (1) Prepare 2.5% sodium pentobarbital in advance. Wild-type rats (WT), Arteridin-overexpressing rats (OE_Arteridin), and Arteridin-knockout rats (KO_Arteridin) were anesthetized with 1 ml of sodium pentobarbital per rat.
[0106] (2) Prepare permeabilization / blocking solution: 3% Triton X-100 + 1% BSA;
[0107] (3) pre-cooled saline, methanol, and 4% paraformaldehyde;
[0108] (4) After the rat is fixed on the foam cover, the chest is opened with a tissue scissor, the right atrial appendage is found, and then the right atrial appendage is cut. A 20 ml syringe is used to perfuse normal saline into the left ventricle until the outflowing fluid is non-bloody. The perfusion is stopped. At this time, the fundus of the rat can be observed to turn white.
[0109] (5) The entire eyeball (n ≥ 3) was removed and placed in pre-cooled 4% paraformaldehyde for fixation for 1 h;
[0110] (6) Perform retinal detachment under a surgical microscope using ophthalmic scissors and forceps in pre-cooled saline;
[0111] (7) Gently pick up the peeled retina and place it between two slides. Place it in pre-cooled methanol for further fixation in a 24-well plate for 30 minutes.
[0112] (8) Place the fixed retina in 3% Triton-100 + 1% BSA permeabilization / blocking solution for permeabilization and blocking at 4°C overnight;
[0113] (9) The next day, IB4-488 dye was diluted with primary antibody diluent at a ratio of 1:200 and the retina was incubated with primary antibody. Because IB4-488 dye is self-fluorescent, it is necessary to protect the retina from light at this step. Wrap the 24-well plate with tin foil for primary antibody incubation at 4°C overnight.
[0114] (10) On the third day, the antibodies in the 24-well plate incubated with IB4-488 dye the previous day were recovered;
[0115] (11) Wash the antibody-incubated retina with physiological saline for 5 minutes each time, for a total of 3 times;
[0116] (12) Carefully pick up the retina and place it on a glass slide;
[0117] (13) Add an appropriate amount of anti-fluorescence quenching agent and carefully cover the cover glass;
[0118] (14) Use nail polish to seal and secure the coverslip to prevent it from sliding;
[0119] (15) Store at 4°C and schedule a photo taking time;
[0120] The results are as follows Figure 6 As shown, from Figure 6 It can be seen that Arteridin overexpression inhibits rat retinal angiogenesis, and Arteridin knockout promotes rat retinal angiogenesis.
[0121] Example 3: Study on the Effect of Arteridin Protein on Tumor Angiogenesis
[0122] This example provides an experimental method for the effect of Arteridin protein on tumor angiogenesis, specifically:
[0123] 1) Construction of adeno-associated virus (AAV) overexpressing Arteridin protein specifically in mouse endothelial cells. We commissioned Hanbio Biotech (Shanghai) Co., Ltd. to construct adeno-associated virus overexpressing Arteridin protein specifically in mouse endothelial cells. Figure 7This is a map of adeno-associated virus that overexpresses mouse endothelial cell-specific Arteridin protein; using pAAV-RC vector plasmid, pHelper vector plasmid and the sequence of the mouse Arteridin ORF region, adeno-associated virus that overexpresses mouse endothelial cell-specific Arteridin protein was prepared through transfection and purification. Among them mouse Arteridin The sequence of the ORF region is: ATGGGAAAGGCGCTTCCCTTTTATCTTAGCCCCTATCCTGTTGATTTCTGGACCAATGCTTCTTTCTCGGACGAAGAACATGAAGACGCTGCTTTATCTAACAGTCACCTCGGAAGAAACGCCATGGTTCCTCCACAAGGGAGATCTGGCCCCGCGTCTTGGATCCTGAGATCTGTGCGAGATCCCGGCTTTGCGCCCTGTCCGCCCTGG AGCTGGATTTATCATCAGTTTAGAATAGCATGGCTACGATGGTGGTGCGGATGGATGGACGAGCCCCGCAAGTGCAGACAGGACAGTCCACATCACCTGCCAAAGCAGCCAGCAATGCAACAGCTCTCCAAGATCAGGCCGACTACAAGGATGACGATGACAAGGATTACAAAGACGACGATGATAAGGACTATAAGGATGATGACGACAAATAG(SEQ ID NO.4)
[0124] 2) Study the effect of Arteridin protein on tumor angiogenesis in vivo through subcutaneous tumor-bearing experiments
[0125] (1) Three weeks in advance, C57BL / 6J mice were divided into two groups. One group was tail-injected with adeno-associated virus overexpressing mouse endothelial cell-specific Arteridin protein, while the other group was tail-injected with control virus.
[0126] (2) Cultivate B16 cells and LLC cells, digest and resuspend the cells to a cell count of 2.5 million / ml;
[0127] (3) Inject 200 μl of cell solution subcutaneously into the mouse forelimb armpit;
[0128] (4) The length and width of the tumors of the two groups of mice injected with B16 cells were measured every 3 days starting from the 6th day. The mice were killed on the 15th day, and the subcutaneous tumors were removed, and the length, width and weight were measured. The microvessels in the tumors were also stained.
[0129] (5) The length and width of the tumors of the two groups of mice injected with LLC cells were measured every 3 days starting from the 9th day. The mice were killed on the 18th day, and the subcutaneous tumors were removed, and the length, width and weight were measured. The microvessels in the tumors were also stained.
[0130] result Figure 8 and Figure 9 As shown in the figure, it can be seen that after endothelial-specific overexpression of Arteridin, the size of subcutaneous tumors in mice was inhibited and intratumoral angiogenesis was reduced.
[0131] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some or all of the technical features therein. These modifications or replacements do not deviate the essence of the corresponding technical solutions from the scope of the technical solutions of the embodiments of the present invention, and they should all be included in the scope of the claims and description of the present invention.
Claims
1. Application of Arteridin protein in the preparation of drugs for inhibiting angiogenesis.
2. The use according to claim 1, characterized in that: The nucleic acid sequence encoding the Arteridin protein is shown as SEQ ID No.
1.
3. The use according to claim 2, characterized in that: The angiogenesis includes endothelial cell angiogenesis, retinal angiogenesis and tumor angiogenesis.
4. The use according to claim 3, characterized in that: The Arteridin protein can inhibit STAT3 phosphorylation and nuclear translocation.
5. The use according to claim 4, characterized in that: Application of reagents for detecting Arteridin protein expression in the preparation of products for the diagnosis and treatment of angiogenesis.
6. The use according to claim 5, characterized in that: The products include Arteridin protein detection reagents.
7. The use according to claim 6, characterized in that: The detection reagent includes a reagent used to detect the expression level of the Arteridin protein encoding gene by a fluorescent quantitative PCR method.
